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Abstract
Background: Prediction of the functional outcome for patients with convulsive status epilepticus (CSE) has been a
challenge. The aim of this study was to characterize the prognostic factors and functional outcomes of patients
after CSE in order to develop a practicable scoring system for outcome prediction.
Methods: We performed a retrospective explorative analysis on consecutive patients diagnosed with CSE between
March, 2008 and November, 2014 in a tertiary academic medical center in northwest China. The modified Rankin
Scale (mRS) was used to measure the functional outcome at three months post discharge.
Results: A total of 132 CSE patients was included, with a median age of 25.5 years and 60.6 % were male. Three
months post discharge, an unfavorable outcome with mRS of 3–6 was seen in 62 (47.0 %) patients, 25 (18.9 %) of
whom died. Logistic regression analysis revealed that encephalitis (p = 0.029), nonconvulsive SE (p = 0.018),
diazepam resistance (p = 0.005), image abnormalities (unilateral lesions, p = 0.027; bilateral lesions or diffuse cerebral
edema, p < 0.001) and tracheal intubation (p = 0.032) were significant independent predictors for unfavorable
outcomes. Based on the coefficients in the model, these predictors were assigned a value of 1 point each, with the
exception of the image, creating a 6-point scoring system, which we refer to as END-IT, for the outcome prediction
of CSE. The area under the receiver operating characteristic curve for the END-IT score was 0.833 and using a cut-
off point of 3 produced the highest sum sensitivity (83.9 %) and specificity (68.6 %). Compared with status
epilepticus severity score (STESS) and Epidemiology-based Mortality score in SE (EMSE), END-IT score showed better
discriminative power and predictive accuracy for the outcome prediction.
Conclusions: We developed an END-IT score with a strong discriminative power for predicting the functional
outcome of CSE patients. External prospective validation in different cohorts is needed for END-IT score.
Background
Convulsive status epilepticus (CSE) is a common, life-
threatening neurological disorder [1]. Even with prompt
treatment, the mortality rate remains high, ranging from
7.6 to 39 % [2], and more than 10 % of survivors develop
neurological and cognitive disabilities [3, 4]. An accurate
quantification of CSE severity and a reliable predictor
of functional outcomes would be beneficial for clini-
cians in optimizing individualized patient management
and communicating with relatives and other health-
care professionals.
Currently, two scores for SE outcome prediction are
available, the Status Epilepticus Severity Score (STESS)
[5, 6] and the Epidemiology based Mortality score in SE
(EMSE) [7]. The STESS was developed from a retrospect-
ive study and was based on four variables at the time of
presentation: history of seizures, age, seizure type, and
consciousness impairment [6]. The EMSE score was de-
rived from a retrospective, exploratory analysis based on
epidemiological data and taking into consideration eti-
ology, age, comorbidity and electroencephalogram (EEG)
data [7]. Both of these scores have been primarily used to
predict survival vs. death in the hospital setting. However,
no scoring system currently exists for the purpose of pre-
dicting the functional outcome of patients with CSE once
they have been discharged.
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Here we performed a retrospective cohort study, on
the basis of a prospective registry for SE, with two aims:
(1) to identify independent prognostic factors associated
with the functional outcome of patients three months
after discharge from the hospital setting by analyzing
demographic data, clinical features, neuroimages, and
the treatment of the disease in the hospital; and (2)
to establish a prognostic score by incorporating these
variables according to their determined relative con-
tributions to the resulting functional outcome.
Methods
Study setting and patients
This retrospective analysis utilized a registry for SE from
the neurological intensive care unit (N-ICU) at Xijing
Hospital, a tertiary academic medical care institution
with 3200-beds in Xi’an, China. All patients with CSE
from March 2008 to November 2014 were recruited for
this study as long as they were older than 12 years of
age. CSE was defined as 30 minutes or more of (1) con-
tinuous motor seizure activity or (2) recurrent seizure
activity without regaining full consciousness between ep-
isodes [8]. Subjects with CSE from cerebral anoxia were
excluded due to the high rate of mortality [9]. All pa-
tients were followed up for at least three months after
discharge from Xijing Hospital. For this, two to three
telephone numbers (both mobile and landline) were col-
lected from the patients’ relatives at the time of registry.
The present study was approved by the ethics committee
of the Xijing Hospital and was carried out in agreement
with Chinese laws and the Helsinki declaration relative
to patients’ rights.
SE treatment procedure
All of the CSE patients were treated according to the
established hospital protocol, which was based upon
published guideline recommendations [10, 11]. Intraven-
ous (IV) diazepam was administered as a first-line anti-
epileptic drug (AED), followed by IV second-line AEDs
if SE persisted (e.g., valproic acid, phenobarbital). If the
first- and second-line AEDs failed to treat the patient,
third-line treatments with IV anesthetics (e.g., midazo-
lam, propofol) were initiated. Ketamine, isoflurane, and a
ketogenic diet were used as a fourth-line therapy.
After admission, each patient received continuous
bedside video-EEG monitoring (Solar 2000 N, Solar
Electronic Technologies Co., Ltd, Beijing, China) for
guiding the AED treatment and detecting the occurrence
of nonconvulsive SE (NCSE). NCSE was defined as more
than 30 minutes of continuous seizure activity seen on an
EEG, with or without subtle motor movements [10, 12].
Upon discharge from the Xijing Hospital, patients were
transferred to secondary hospitals where they received re-
habilitation treatment.
Definition of the predictor variables
The following predictor variables with a possible associ-
ation with the recovery of CSE were chosen for statistical
analysis. Three of the chosen variables concerned the
demographic and medical history: (1) age; (2) gender; and
(3) history of epilepsy, coded as being present or absent.
Two variables were extracted from the clinical
examination on N-ICU admission: (1) Glasgow Coma
Scale (GCS), dichotomized as a score ranging from
3–8 or ranging from 9–15; and (2) pupillary light reflex,
coded as sensitive on both sides, or slow or absence on
one side or two sides.
One variable concerned the SE etiology. Given that en-
cephalitis constitutes most of the SE cases, presenting as
an acute symptomatic etiology in developing countries,
and is related to poor outcome [2, 13–17], the SE etiology
was categorized as either encephalitis or non-encephalitis.
Four variables were extracted from the SE treatment:
(1) resistance to diazepam, coded as Yes or No; (2) SE
duration (time to seizure control), dichotomized as < 2
hrs or ≥ 2 hrs, which is based on previous studies showing
that CSE persisting more than 2 hrs was often defined as
refractory SE and the patients with CSE exceeding 2 hrs
were more likely to have a poor outcome than those with
less than 2 hrs [18–20]; (3) drug induced coma; and (4)
use of three or more types of intravenous AEDs, both
coded as Yes or No.
Three variables concerned comorbidity: (1) complicated
with NCSE; (2) tracheal intubation, both coded as Yes or
No; and (3) the Charlson’s Comorbidity Index (CCI), clas-
sified into three categories: 0 point, 1 to 2 points, 3 points
or more [7, 21].
Brain images were also considered as a predictor vari-
able. According to the distribution of responsible lesions
on images for SE, we classified brain images into three dif-
ferent categories: no responsible lesion, unilateral respon-
sible lesions, and bilateral responsible lesions or diffuse
cerebral edema. We reviewed the first and subsequent
study findings of computed tomography (CT) and mag-
netic resonance imaging (MRI) scans after SE onset and
only recorded the most serious findings. The classification
of the image was determined by two experienced neurolo-
gists unaware of the final outcome, who based their deci-
sions on both pictures and the official radiology reports,
and a consensus was reached.
Definition of outcomes
The clinical outcome was independently assessed three
months after discharge from the Xijing Hospital by a
trained neurologist, who was blinded to the clinical data,
via a telephone interview. The mRS was used to measure
the disability of the patients [22]; this scale comprises
seven different levels of outcomes ranging from 0 (no
symptoms) to 5 (severe disability) and 6 (death). In cases
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where the patient was unable to complete the interview,
the mRS score was determined by interviewing the pa-
tient’s caregiver. For the purpose of statistical analysis,
we defined the score range of 0–2 (independence) of
mRS as a favorable outcome, and the score range of 3–6
(death or dependence with regard to activities of daily
living) as an unfavorable outcome.
Statistical analysis
Continuous variables were expressed as mean ± standard
deviation (normally distributed), as medians and inter-
quartile ranges (IQR, not normally distributed), or, if
they were categorical variables, they were expressed as
counts and percentages. We first conducted univariate
comparisons for each outcome using the χ2 test for the
categorical variables and the Mann–Whitney U test or
Student’s t-test for the continuous variables. A backward
stepwise multivariate logistic regression was then per-
formed in order to identify independent outcome predic-
tors among those found to have a p < 0.05 on the
univariate analysis. Points were then assigned to each in-
dependent risk factor by dividing its β-coefficient in the
model by the lowest β-coefficient and rounding to the
nearest integer. Thus, a predictive score was created for
each subject by adding the points determined for each
factor, with higher scores corresponding to a higher like-
lihood of an unfavorable outcome for CSE patients. The
performance of the predictive score was then evaluated
by calculating the area under the receiver operating
characteristic curve (ROC). Using the ROC curve, the
best cutoff value of the score that was able to predict the
primary end point was determined. Predictive accuracy
was calculated as the average of sensitivity and specifi-
city. Statistical analyses were performed using the SPSS
18.0 and Matlab 2012a. All tests were two-sided, and
a p value of less than 0.05 was considered statistically
significant in univariate and multivariate analyses, as
was a p value lower than 0.0083 for comparison tests
on performances [23].
Results
The patient flow chart is shown in Fig. 1. A total of 132
CSE patients were included in the study, each of whom
was able to be followed up. The median age of the sam-
ple was 25.5 (IQR, 17–48) years and 60.6 % of them
were men. The most common cause of CSE in our sam-
ple was encephalitis, accounting for 35.6 %, followed by
AED low levels/withdrawal (13.6 %) and cerebrovascular
diseases (11.4 %), as shown in Table 1. At three months
post discharge, 70 (53.0 %) patients presented with a
Fig. 1 Flow chart describing the characteristics of the study sample
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favorable outcome (mRS 0–2), while 62 (47.0 %) patients
had an unfavorable outcome (mRS 3–6), among whom
25 (18.9 %) died.
The demographic, clinical, and neuroimage features of
the patients during hospitalization in the N-ICU are
summarized in Table 2 and Additional file 1. Univariate
analysis indicated that age (p = 0.075), gender (p = 0.387),
history of epilepsy (p = 0.821), pupillary light reflex on
admission (p = 0.109), and CCI (p = 0.260) did not correl-
ate significantly with the outcome noted at three months
post discharge (Table 2). An unfavorable outcome was
more likely if the patient had initially presented with a
lower GCS score during the time of admission, experi-
enced diazepam resistance and had a longer SE duration,
suffered from encephalitis and tracheal intubation, re-
ceived more than three intravenous AEDs and had a drug
induced coma, progressed to NCSE, and displayed abnor-
mal brain images (p < 0.05). These variables were then en-
tered into the multivariate logistic regression model, and
the results indicated that only encephalitis, NCSE, di-
azepam resistance, imaging abnormalities, and tracheal
intubation were significant independent predictors for an
unfavorable outcome (Table 3).
In order to establish a straightforward prognostic indi-
cator to be used in clinical practice, we developed a
scoring system comprised of the aforementioned five
risk factors and named it END-IT, which is an acronym
for encephalitis, NCSE, diazepam resistance, image ab-
normalities and tracheal intubation. Each of the five
identified factors was then assigned an integer score
based on the magnitude of their determined contribu-
tion to adverse events in the multivariate model. The de-
tailed allocation of the scoring points is listed in Table 4.
Each of the variables was assigned one point, with the
exception of the image, in which unilateral lesions were
given one point and bilateral lesions or the presence
of diffuse cerebral edema were given two points. The
outcome of CSE can be estimated for an individual pa-
tient by summing the points of each predictor result-
ing in a total point score ranging from 0 to 6. The
probability of unfavorable outcome increases as the
score increases (Fig. 2).
The ROC curve for the weighted score was shown to
have good discriminative power with an area under the
curve (AUC) of 0.833 (95 % CI, 0.758–0.892) (Fig. 3).
The validity of the END-IT score in assessing the three-
month post discharge outcome in this cohort is summa-
rized in Table 5. The cut-off point of 3 of 6 produced
the optimal sum of sensitivity and specificity for the pre-
diction of an unfavorable outcome. Fifty-two (83.9 %) of
the 62 patients with an unfavorable outcome had an
END-IT score of 3 or greater and 48 (68.6 %) of the 70
patients who presented with a favorable outcome had a
score of 0 to 2. Using this cutoff value, the END-IT score
had a high sensitivity of 83.9 % with a positive predictive
value (PPV) of 70.3 % and a specificity of 68.6 % with a
negative predictive value (NPV) of 82.8 % for the predic-
tion of functional outcomes (Table 5). The new prognos-
tic score achieved a predictive accuracy of 76.22 %.
STESS and EMSE-score using etiology-age-comorbidity-
EEG (EMSE-EACE) were also calculated in this study
cohort and compared with the END-IT score in the
predictive power of outcome. Figure 3 showed that
the END-IT score (AUC = 0.833, accuracy = 76.22 %)
had better discriminative power and predictive accuracy
than STESS (AUC = 0.573, accuracy = 57.98 %) and
EMSE-EACE (AUC = 0.683, accuracy = 67.70 %) in the
prediction of functional outcomes. The comparisons of
sensitivity, specificity, positive (PPV) and negative (NPV)
predictive value and number of correctly classified (CC)
patients between STESS, EMSE-EACE and END-IT are
shown in Fig. 4. END-IT score was significantly superior
to STESS with cutoff levels 3 and 4 (STESS-3: 3 or more
points indicate bad outcome, i.e., death; STESS-4: 4 or
more points indicate bad outcome, i.e., death): NPV of
Table 1 Causes of convulsive status epilepticus





Acute symptomatic 81 (61.4) 36 (51.4) 45 (72.6)
Remote symptomatic 26 (19.7) 15 (21.4) 11 (17.7)
Progressive symptomatic 5 (3.8) 4 (5.7) 1 (1.6)
Unknown 20 (15.2) 15 (21.4) 5 (8.1)
Individual categories
Encephalitis 47 (35.6) 15 (21.4) 32 (51.6)
Viral 37 (28.0) 13 (18.6) 24 (38.7)
Tuberculous 4 (3.0) 2 (2.9) 2 (3.2)
Autoimmune 4 (3.0) 0 4 (6.5)
Bacterial 1 (0.8) 0 1 (1.6)
Cryptococcal 1 (0.8) 0 1 (1.6)
AED low levels/withdrawal 18 (13.6) 6 (8.6) 12 (19.4)
Acute cerebrovascular diseases 15 (11.4) 7 (10.0) 8 (12.9)
Metabolism/alcoholism 11 (8.3) 10 (14.3) 1 (1.6)
Acute trauma 2 (1.5) 2 (2.9) 0
Remote trauma 12 (9.1) 9 (12.9) 3 (4.8)
Tumor 3 (2.3) 2 (2.9) 1 (1.6)
Systematic infection 2 (1.5) 2 (2.9) 0
Mitochondrial encephalopathy 1 (0.8) 1 (1.4) 0
Cerebral lupus 1 (0.8) 1 (1.4) 0
Cryptogenic 12 (9.1) 10 (14.3) 2 (3.2)
Two or more causes 8 (6.1) 5 (7.1) 3 (4.8)
mRS modified Rankin Scale, AED antiepileptic drug
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END-IT 82.76 %, STESS-3 55.45 % (p = 0.0000030), and
STESS-4 52.80 % (p = 0.000000099); CC of END-IT 75.76
%, STESS-4 52.27 % (p = 0.00037). Compared with EMSE-
EACE with cutoff 64, END-IT score showed a better ten-
dency in NPV and CC but there was no statistically signifi-
cant difference between them.
Discussion
A straightforward prognostic scoring system was devel-
oped in this study in order to determine the functional
outcome of patients with CSE. To make full use of the
available clinical data and to systematically consider the
progression of SE, our score was initially designed to in-
corporate the demographics, clinical characteristics, and
treatment responses, as well as the available neuroi-
mages. The statistical analysis showed that encephalitis,
NCSE, diazepam resistance, image abnormalities and
tracheal intubation were significant independent predic-
tors of functional outcome at three months post discharge
from the hospital. Using these predictors and their regres-
sion coefficients in the model, we developed a simple six-
point score, termed END-IT, in order to predict the prob-
ability of an unfavorable outcome in CSE. The END-IT
score was shown to have a good predictive accuracy as
well as good discriminative power, thus providing families
and clinicians with better information regarding the prog-
nosis. As the function outcome was known during the
process of score generation, this study is explorative, i.e.,
hypothesis generating.
Given that unfavorable outcome at three months after
discharge could be caused by many other factors inde-
pendent of SE, e.g., car accidents, myocardial infarction,
Table 3 Multivariable analysis
Variable Coefficient Odds ratio (95 % CI) P Weighted integer coefficient
Encephalitis 1.105 3.018 (1.119 to 8.141) 0.029 1
NCSE 1.072 2.922 (1.201 to 7.109) 0.018 1
Diazepam resistance 1.361 3.899 (1.519 to 10.007) 0.005 1
Image
unilateral lesions 1.479 4.386 (1.188 to 16.199) 0.027 1
bilateral lesions/diffuse cerebral edema 1.979 7.236 (2.414 to 21.690) <0.001 2
Tracheal intubation 1.093 2.982 (1.099 to 8.092) 0.032 1
NCSE nonconvulsive status epilepticus
Table 2 Univariate analysis
Variable Total (n = 132) mRS:0–2 (n = 70) mRS:3–6 (n = 62) P
Age, median (IQR), y 25.5 (17.0, 48.0) 24 (17.0, 34.5) 31 (18.8, 54.3) 0.075 (Mann–Whitney U)
Gender, male, No. (%) 80 (60.6) 40 (57.1) 40 (64.5) 0.387 (χ2)
History of epilepsy, No. (%) 54 (40.9) 28 (40.0) 26 (41.9) 0.821 (χ2)
GCS on admission 3–8, No. (%) 54 (40.9) 22 (31.4) 32 (51.6) 0.019 (χ2)
Pupillary light reflex on admission, slow or absence, No. (%) 36 (27.3) 15 (21.4) 21 (33.9) 0.109 (χ2)
Encephalitis, No. (%) 47 (35.6) 15 (21.4) 32 (51.6) <0.001 (χ2)
Complicated with NCSE, No. (%) 63 (47.7) 23 (32.9) 40 (64.5) <0.001 (χ2)
Diazepam resistance, No. (%) 82 (62.1) 32 (45.7) 50 (80.6) <0.001 (χ2)
Image 0.007 (χ2)
unilateral lesions, No. (%) 28 (21.2) 16 (22.9) 12 (19.4)
bilateral lesions/diffuse cerebral edema, No. (%) 63 (47.7) 25 (35.7) 38 (61.3)
Tracheal intubation, No. (%) 41 (31.1) 11 (15.7) 30 (48.4) <0.001 (χ2)
Duration >2 h, No. (%) 81 (61.4) 34 (48.6) 47 (75.8) 0.001 (χ2)
Drug induced coma, No. (%) 42 (31.8) 15 (21.4) 27 (43.5) 0.006 (χ2)
Usage of ≥3 types vAEDs, No. (%) 73 (55.3) 32 (45.7) 41 (66.1) 0.019 (χ2)
CCI 0.260 (χ2)
1–2 36 (27.3) 17 (24.3) 19 (30.6)
3 or more 18 (13.6) 5 (7.1) 13 (21.0)
mRS modified Rankin Scale, IQR interquartile range, GCS Glasgow coma scale, NCSE nonconvulsive status epilepticus, SE status epilepticus, vAEDs intravenous
antiepileptic drugs, CCI Charlson’s Comorbidity Index
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or trauma, it is necessary to exclude these influences in
investigating the functional outcome of CSE. Thus, for
those patients with unfavorable outcome, we inquired if
other risk factors had been encountered after discharge.
However, there was no such case in this study cohort.
The age of patients had been previously determined by
other studies to be an important risk factor for mortality
after SE [5, 24–26]. In this study, we did not find a sig-
nificant relationship between age and functional out-
come. This could be partially explained by the fact that
there is no direct relationship between age and the se-
verity of clinical conditions, and the latter has an im-
portant influence on patients’ recovery. However, it
should be noted that the age distribution in the sample
group used in our study is different from previous stud-
ies. STESS which was created by Rossetti et al. was
based on a SE database of 127 episodes occurring in 107
adult patients, in which more than 30 % of the patients
were ≥ 65 years of age [24], whereas the median age of
our sample group was 25.5 (IQR, 17–48) years of age,
and only 11 of the 132 (8.33 %) patients were over 65
years of age. Given that older patients are less resistant
to complications of SE and its treatment, such as
pneumonia, this could result in a higher incidence of
unfavorable outcomes in older patients. A study with
a larger sample size and a stratification analysis is
needed to clarify this.
Recent studies have indicated that encephalitis is an
acute symptomatic etiology present in most cases of SE
and is related to a poor prognostic outcome in develop-
ing countries [2, 13–17]. Patients with encephalitis were
also determined in this study to constitute 35.6 % of all
cases of SE, 68.1 % of whom had a score between 3 and
6 at three months post discharge, indicative of an un-
favorable functional outcome, which is consistent with
the results from previous studies. Therefore, encephalitis
was chosen as an etiology variable in the prediction of
the functional outcome for CSE patients, which was
proven to be an independent predictor by multivariate
logistic regression analysis.
NCSE in the END-IT scoring system refers to subtle
SE. Subtle SE, a term used to describe SE with subtle
clinical features of myoclonic jerks or nystagmus in
association with EEG discharges, is a form of NCSE
that develops from CSE if the latter has been treated
insufficiently [27, 28]. A considerable percentage of
Table 4 Point allocation for the END-IT score based on
regression coefficients





Diazepam resistance Yes 1
No 0
Image bilateral lesions/diffuse cerebral edema 2
unilateral lesions 1
no responsible lesion 0
Tracheal intubation Yes 1
No 0
NCSE nonconvulsive status epilepticus
Fig. 2 END-IT scores and their corresponding predicted estimates for an unfavorable outcome
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patients (47.7 %) suffering from subtle SE, which
might be due to structural or metabolic brain damage
or an initial insufficient treatment, were found in our
study. Previous studies have shown that the presence
of NCSE, once CSE was under control, was associated
with significant mortality and poor functional outcome
[29, 30]. Similarly, we also found that patients with NCSE
had a higher proportion of unfavorable outcomes than
those without NCSE.
Impairment of consciousness at the onset of SE can be
indicative of extreme severity, and has also been shown
to be independently related to death in previous retro-
spective studies [24, 30, 31]. In this study, we used a
GCS score and a pupillary light reflex on N-ICU admis-
sion in order to evaluate the level of consciousness of
each patient with SE. However, a significant relationship
between these two variables and the functional outcome
was not found. This may be due to the fact that patients
on N-ICU admission have received an intravenous diaze-
pam injection in the ambulance or emergency room,
which could affect their level of consciousness.
Refractory SE is defined as the presence of SE either
clinically or as determined by electrographic examin-
ation despite treatment with adequate doses of an initial
benzodiazepine followed by a second acceptable AED
[10, 32]. The long-term outcome of 596 cases with re-
fractory SE was analyzed by Ferlisi et al., the results of
which indicated that 35 % of the patients had died, 13 %
had a severe neurological deficit, and only 35 % recov-
ered to baseline [33]. Recent prospective studies have
also shown that refractory SE appeared to be strongly
associated with poor outcomes [34, 35]. Considering the
controversy surrounding the definition of refractory SE,
i.e., the number of AEDs that patients need to have
failed and the duration of SE after the initiation of treat-
ment [10], we chose several variables that reflect the fea-
tures of refractory SE, including diazepam resistance, SE
duration, use of three or more types of intravenous
AEDs, a drug induced coma, and tracheal intubation, as
candidate predictors when performing the statistical ana-
lysis. Although these variables were shown to be related
to an unfavorable outcome in the univariate analysis,
multivariate analysis demonstrated that only tracheal in-
tubation functioned as an independent predictor. This
could be explained by the fact that tracheal intubation
was a consequence possibly linked to diazepam resist-
ance, a longer SE duration, usage of three or more types
of intravenous AEDs, and a drug induced coma. Mean-
while, tracheal intubation implied a high risk of respira-
tory failure, mechanical ventilation, pneumonia, and a
longer ICU stay, which were the primary reasons for the
poor outcome observed for refractory SE [36, 37].
Recently, Kilbride et al. investigated the clinical out-
comes of 63 patients with prolonged refractory SE and
found that a normal neuroimage at the onset of SE was as-
sociated with a favorable outcome [38]. In an effort to
clarify the role of neuroimaging findings in the prediction
Table 5 Performance of the END-IT score
End-it Score Sensitivity (95 % CI) Specificity (95 % CI) PPV (95 % CI) NPV (95 % CI)
0 100.00 (94.2–100.0) 0.00 (0.0–5.1) 47.0 (38.2–55.8)
1 98.39 (91.3–100.0) 11.43 (5.1–21.3) 49.6 (40.5–58.8) 88.9 (48.9–99.8)
2 98.39 (91.3–100.0) 28.57 (18.4–40.6) 55.0 (45.2–64.4) 95.2 (75.5–99.9)
3 83.87 (72.3–92.0) 68.57 (56.4–79.1) 70.3 (58.5–80.3) 82.8 (70.4–91.5)
4 66.13 (53.0–77.7) 85.71 (75.3–92.9) 80.4 (66.9–90.2) 74.1 (63.1–83.2)
5 32.26 (20.9–45.3) 95.71 (88.0–99.1) 87.0 (65.8–97.4) 61.5 (51.7–70.6)
6 8.06 (2.7–17.8) 100.00 (94.9–100.0) 100.0 (47.8–100.0) 55.1 (46.0–63.9)
PV was study population specific
PPV positive predictive value, NPV negative predictive value
Fig. 3 Receiver operating characteristic curve (ROC) for END-IT, Status
Epilepticus Severity Score (STESS) and Epidemiology based Mortality
score in SE using etiology-age-comorbidity-EEG (EMSE-EACE). END-IT:
AUC = 0.833, 95 % CI: 0.766–0.900; STESS: AUC = 0.573, 95 % CI:
0.478–0.668; EMSE-EACE: AUC = 0.683, 95 % CI: 0.590–0.776
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of functional outcomes, taking into account the extent of
brain damage evident on CT/MRI brain scans, we classi-
fied them into three types, in which unilateral responsible
lesions and bilateral responsible lesions or the presence
of diffuse cerebral edema were all significantly associ-
ated with unfavorable outcomes. In light of their contri-
bution in multivariate models, unilateral lesions were
assigned 1 point, whereas bilateral lesions or diffuse
cerebral edema were each given 2 points in the END-IT
scoring system. However, because many patients under-
went only one imaging examination during N-ICU
hospitalization, our study could not demonstrate if an
evolution of imaging findings is predictive of a func-
tional outcome.
The limitations of this study should be noted. First,
the score was developed based upon data extracted from
a relatively small sample size from a single university ter-
tiary medical center. Thus, the results may not be able
to be extrapolated to other settings or populations;
hence, further validation in different settings is needed.
Second, we collected the functional outcome data at
three months after discharge, but not three months after
onset of CSE. Since the functional outcome is time
dependent, it could be influenced by some other factors,
e.g., the discharge habits of the different involved physi-
cians, and shortness of hospital beds for fast discharge.
Third, our scoring system did not take into account
serological variables, e.g., serum neuron-specific enolase
(NSE). Although a few reports have previously shown
that NSE may be a promising in vivo marker for brain
injury after SE [39–42], its exact role in prognosis of
CSE awaits further research. Fourth, we did not examine
the role of certain EEG patterns in outcome prediction.
Long-term EEG monitoring revealed that some patients
often presented with several different kinds of EEG pat-
terns, e.g., burst-suppression and postictal discharges could
coexist with difference in sequence, which makes it difficult
to interpret the relationship between a specific EEG pat-
tern and a functional outcome. Lastly, we collected the
follow-up information on function outcome of patients
through telephone interviews but not clinical examination.
This might result in some small biases in outcome infor-
mation, since mRS based on telephone interview could be
influenced by some complicating factors.
Conclusions
In this study, we developed a straightforward and prac-
ticable scoring system, termed END-IT, to predict the
three-month functional outcome post discharge for CSE
patients. The score comprises five in-hospital variables:
encephalitis, NCSE, diazepam resistance, image, and tra-
cheal intubation, and showed good predictive accuracy
and discrimination power. However, it should be re-
membered that the END-IT score simply predicts the
probability of functional outcome, with no judgment be-
ing made as to whether the patients continue to receive
intensive treatment or not. Future studies are required
for further validation and improvements upon this scor-
ing system.
Key messages
 Forty-seven percent of patients with convulsive
status epilepticus lasting more than 30 minutes
suffered an unfavorable outcome.
 Encephalitis, NCSE, diazepam resistance, image
abnormalities and tracheal intubation were
independent predictors for unfavorable outcome.
Fig. 4 Comparisons of sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV), number of correctly classified
(CC) patients between STESS-3, STESS-4, EMSE-EACE-64 and END-IT. Sensitivity: *p = 0.0000000028, **p = 0.000000000000046; specificity: *p =
0.00012; NPV: *p = 0.0000030, **p = 0.000000099; correctly classified: *p = 0.00037. Level of significance corrected for multiple testing p < 0.00833.
STESS status epilepticus severity score, EMSE epidemiology based mortality score
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 Based on these five independent predictors and their
coefficients in the logistic regression model, we
established a 6-point scoring system, termed END-IT.
 The END-IT score showed good discriminative
power as well as predictive accuracy.
Additional file
Additional file 1: Baseline characteristics of 132 patients. (DOC 42 kb)
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